Investigators are optimistic that LN-145, an autologous tumor-infiltrating lymphocyte investigational therapy, could be a potential treatment option for patients with recurrent, metastatic, or persistent cervical cancer.
Sponsored Content by Iovance Biotherapeutics, Inc
Advertisement
Articles by Sponsored Content by Iovance Biotherapeutics, Inc
Advertisement
Latest Updated Articles
TIL Therapy May Provide Second-Line Option for Cervical CancerPublished: October 25th 2018 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
3
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
4
SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma
5